93 pending office actions • 73 clients
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19310181 | Untitled | Yeda Research And Development Co., Ltd. | LIPPOLIS, ALEXANDRA ROSE | 1637 | Non-Final OA | |
| 19376086 | Untitled | Aveo Pharmaceuticals, Inc. | SIMMONS, CHRIS E | 1622 | Non-Final OA | |
| 18857976 | MEDICAL IMPLANT FOR TREATMENT OF A SCAPULA FRACTURE | UNIVERSITEIT GENT | KU, SI MING | 3775 | Final Rejection | Oct 18, 2024 |
| 18710905 | METHOD TO SYNTHESIZE CHITIN OLIGOSACCHARIDES | Institut Químic de Sarrià | EDWARDS, JESSICA FAYE | 1657 | Non-Final OA | May 16, 2024 |
| 18629077 | Use of Terminal Transferase Enzyme in Nucleic Acid Synthesis | Nuclera Ltd. | CONSTANTINE, CHARLES Z | 1657 | Non-Final OA | Apr 08, 2024 |
| 18696722 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | Halda Therapeutics Opco, Inc. | SHAMEEM, GOLAM M | 1621 | Non-Final OA | Mar 28, 2024 |
| 18609420 | METHODS OF TREATING METABOLIC DISORDERS ASSOCIATED WITH LIPODYSTROPHIES AND DEFECTS IN INSULIN PRODUCTION OR SIGNALING | Novartis AG | SAOUD, CHRISTINE J | 1645 | Non-Final OA | Mar 19, 2024 |
| 18690456 | NUCLEIC ACID POLYMERASE AND ITS USE IN PRODUCING NON-DNA NUCLEOTIDE POLYMERS | UNITED KINGDOM RESEARCH AND INNOVATION | SWIFT, CANDICE LEE | 1657 | Non-Final OA | Mar 08, 2024 |
| 18580737 | PARTICLE DELIVERY OF THYROID HORMONE RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF MASSACHUSETTS | GOTFREDSON, GAREN | 1619 | Non-Final OA | Jan 19, 2024 |
| 18416004 | METHODS AND COMPOSITIONS TO INHIBIT TOLERANCE TO OPIOIDS | Sen-Jam Pharmaceutical Inc. | GULLEDGE, BRIAN M | 1699 | Non-Final OA | Jan 18, 2024 |
| 18572385 | METHODS OF TREATING MEDICAL CONDITIONS AND INHIBITING LINE1 REVERSE TRANSCRIPTASE USING A SUBSTITUTED ADENINYL-PROPYLOXY PHOSPHONIC ACID OR RELATED COMPOUND | Rome Therapeutics, Inc. | SZNAIDMAN, MARCOS L | 1628 | Non-Final OA | Dec 20, 2023 |
| 18541560 | Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections | Sen-Jam Pharmaceutical Inc. | HOWELL, THEODORE R | 1628 | Non-Final OA | Dec 15, 2023 |
| 18538201 | DUAL-WAVELENGTH LASER SYSTEMS AND MATERIAL PROCESSING UTILIZING SUCH SYSTEMS | Panasonic Intellectual Property Management Co., Ltd. | KIRKWOOD, SPENCER HAMMETT | 3761 | Non-Final OA | Dec 13, 2023 |
| 18536781 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PIPERIDINYL-METHYL-PURINE AMINE AND THEIR USE IN TREATING DISEASES AND CONDITIONS | K36 Therapeutics, Inc. | KASSA, TIGABU | 1619 | Non-Final OA | Dec 12, 2023 |
| 18516381 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | Halda Therapeutics Opco, Inc. | ELENISTE, PIERRE PAUL | 1622 | Non-Final OA | Nov 21, 2023 |
| 18563277 | ALKALINE PHOSPHATASE-BASED TREATMENTS OF CELIAC DISEASE | Theriva Biologics, Inc. | DAVIS, RUTH A | 1699 | Non-Final OA | Nov 21, 2023 |
| 18561644 | METHODS OF TREATING MEDICAL CONDITIONS AND INHIBITING LINE1 REVERSE TRANSCRIPTASE USING A SUBSTITUTED 4-FLUORO-2,5-DIHYDROFURANYL PHOSPHONIC ACID OR RELATED COMPOUND | Rome Therapeutics, Inc. | KRISHNAN, GANAPATHY | 1693 | Non-Final OA | Nov 16, 2023 |
| 18560260 | ENZYMES, HOST CELLS, AND METHODS FOR PRODUCTION OF ROTUNDONE AND OTHER TERPENOIDS | Manus Bio Inc. | SELWANES, JOHN PAUL | 1651 | Non-Final OA | Nov 10, 2023 |
| 18288435 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETIC RETINOPATHY AND RELATED CONDITIONS | Opus Genetics, Inc. | DEKARSKE, MADELINE MCGUIRE | 1622 | Non-Final OA | Oct 26, 2023 |
| 18557277 | METHODS AND COMPOSITIONS RELATED TO CELL-CYCLE RNA's | UNIVERSITY OF PORTSMOUTH | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Non-Final OA | Oct 25, 2023 |
| 18556599 | METHODS AND COMPOSITIONS FOR TREATING MYDRIASIS, GLAUCOMA, AND OTHER OCULAR CONDITIONS | Opus Genetics, Inc. | DAHLIN, HEATHER RAQUEL | 1629 | Non-Final OA | Oct 20, 2023 |
| 18553954 | BUILDING MATERIALS | Dmat S.r.l. | GREEN, ANTHONY J | 1731 | Non-Final OA | Oct 04, 2023 |
| 18468939 | ALZHEIMER’S DISEASE PREVENTION AND TREATMENT WITH LOW INTENSITY MAGNETIC STIMULATION APPLIED AT PHYSIOLOGICALLY RELEVANT FREQUENCIES | Actipulse Neuroscience, Inc. | KOHUTKA, BROOKE NICOLE | 3791 | Non-Final OA | Sep 18, 2023 |
| 18282329 | GAMMA DELTA T-CELL COSTIMULATION | Shattuck Labs, Inc. | JOHNSON, TIRONE DEREK | 1675 | Non-Final OA | Sep 15, 2023 |
| 18367631 | SALTS AND ESTERS OF APX3330 AND THERAPEUTIC USES THEREOF | Opus Genetics, Inc. | ROMERO, KRISTEN WANG | 1624 | Non-Final OA | Sep 13, 2023 |
| 18549771 | NOVEL METHOD | Babraham Institute | SCHWECHTER, BRANDON ROSS | 1674 | Non-Final OA | Sep 08, 2023 |
| 18280712 | CHIMERIC PROTEINS IN AUTOIMMUNITY | Shattuck Labs, Inc. | NICKOL, GARY B | 1643 | Non-Final OA | Sep 07, 2023 |
| 18279451 | COMBINATION THERAPIES WITH SIRP ALPHA-BASED CHIMERIC PROTEINS | Shattuck Labs, Inc. | LU, CHENG | 1642 | Non-Final OA | Aug 30, 2023 |
| 18546864 | DNASE 1-LIKE 2 ENGINEERED FOR MANUFACTURING AND USE IN THERAPY | Neutrolis, Inc. | LANKFORD JR, LEON B | 1657 | Non-Final OA | Aug 17, 2023 |
| 18275880 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-Biotix Therapeutics, Inc. | VAJDA, KRISTIN ANN | 1622 | Non-Final OA | Aug 04, 2023 |
| 18270285 | INSECT REPELLENT COMPOSITIONS | Manus Bio Inc. | AGUIRRE, AMANDA L | 1626 | Non-Final OA | Jun 29, 2023 |
| 18269036 | METHODS AND COMPOSITIONS RELATED TO BCL2 AND BIM HETERODIMER ANTIBODIES | Eutropics Pharmaceuticals, Inc. | MACFARLANE, STACEY NEE | 1675 | Non-Final OA | Jun 22, 2023 |
| 18267885 | RNAI AGENT FOR INHIBITING HBV EXPRESSION AND USE THEREOF | Olix Pharmaceuticals, Inc. | TATGE, LEXUS MARC | 1637 | Non-Final OA | Jun 16, 2023 |
| 18257767 | TRANSGENIC ANIMALS AND PREPARATIONS THEREOF FOR BIOREMEDIATION | Entozyme Pty Ltd. | STEADMAN, DAVID J | 1656 | Non-Final OA | Jun 15, 2023 |
| 18334909 | COMPOSITIONS FOR USE IN THE TREATMENT OF CHD2 HAPLOINSUFFICIENCY AND METHODS OF IDENTIFYING SAME | Yeda Research And Development Co. Ltd. | LIPPOLIS, ALEXANDRA ROSE | 1637 | Non-Final OA | Jun 14, 2023 |
| 17996343 | STABLE DIGLYCERIDE EMULSIONS AND METHODS FOR TREATING ORGAN INJURY | The Trustees of Columbia University in the City of New York | CORNET, JEAN P | 1628 | Non-Final OA | Jun 13, 2023 |
| 18265603 | NUCLEIC ACID MOLECULE FOR INDUCTION OF ASYMMETRIC RNAI FOR INHIBITING EXPRESSION OF ROR-BETA | Olix Pharmaceuticals, Inc. | REGA, KYLE THOMAS | 1636 | Non-Final OA | Jun 06, 2023 |
| 18265048 | METHODS OF TREATING CANCER USING TIGIT-AND LIGHT-BASED CHIMERIC PROTEINS | Shattuck Labs, Inc. | ABBAS, SYED JARAR | 1674 | Non-Final OA | Jun 02, 2023 |
| 18325283 | BI-FUNCTIONAL CHIMERIC PROTEINS AND USES THEREOF | UNIVERSITEIT GENT | LI, RUIXIANG | 1674 | Non-Final OA | May 30, 2023 |
| 18037628 | METHODS OF IDENTIFYING GAMMA DELTA T CELL-MODULATING AGENTS | Shattuck Labs, Inc. | POHNERT, STEVEN C | 1683 | Non-Final OA | May 18, 2023 |
| 18034120 | GENOME-MODIFIED BACTERIAL STRAINS FOR LARGE SCALE BIOPROCESSES | Manus Bio Inc. | HAUK TEODORO, PRICILA NMN | 1645 | Non-Final OA | Apr 27, 2023 |
| 18033403 | HOMODIMERIC AND HETERODIMERIC PROTEINS COMPRISING BUTYROPHILIN | Shattuck Labs, Inc. | XIAO, YAN | 1642 | Non-Final OA | Apr 24, 2023 |
| 18033252 | GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR MUTANTS | Partner Therapeutics, Inc. | ABBAS, SYED JARAR | 1674 | Non-Final OA | Apr 21, 2023 |
| 18302364 | TARGETED THERAPEUTIC AGENTS AND USES THEREOF | UNIVERSITEIT GENT | STOICA, ELLY GERALD | 1647 | Non-Final OA | Apr 18, 2023 |
| 18187943 | SILICA FIBER COMPOSITIONS AND METHODS OF USE | American Nano, LLC | BECKHARDT, LYNDSEY MARIE | 1613 | Final Rejection | Mar 22, 2023 |
| 18026391 | CLINICAL DOSING OF SIRP1A CHIMERIC PROTEIN | Shattuck Labs, Inc. | MARTINEZ, TARA L | 1654 | Non-Final OA | Mar 15, 2023 |
| 18179178 | METHODS FOR TREATING CHRONIC RHINOSINUSITIS | Optinose, Inc. | JONES, AISLINN MOIRA | 3785 | Non-Final OA | Mar 06, 2023 |
| 18111975 | PRODUCTION OF ANTIGEN-SPECIFIC T-CELLS | The Johns Hopkins University | KIM, TAEYOON | 1631 | Non-Final OA | Feb 21, 2023 |
| 18020734 | METHOD FOR THE TREATMENT OF WWOX ASSOCIATED DISEASES | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | BATES, KEENAN ALEXANDER | 1631 | Non-Final OA | Feb 10, 2023 |
| 18019959 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASE ASSOCIATED WITH BETA CORONAVIRUS INFECTION | Sen-Jam Pharmaceutical LLC | LEE, ANDREW P | 1691 | Non-Final OA | Feb 06, 2023 |
| 18040559 | MULTIPLEXED ANALYTE DETECTION | VITAL BIOSCIENCES INC. | MARCSISIN, ELLEN JEAN | 1677 | Non-Final OA | Feb 03, 2023 |
| 18163026 | TARGETED MODIFIED IL-1 FAMILY MEMBERS | Centre Hospitalier Regional Universitaire De Montpellier | JIANG, DONG | 1674 | Non-Final OA | Feb 01, 2023 |
| 18017927 | SAMPLE HANDLING FOR DIAGNOSTICS | Qsm Diagnostics, Inc. | SUN, CAITLYN MINGYUN | 1795 | Non-Final OA | Jan 25, 2023 |
| 18015622 | ISOTONIC LIPID EMULSION | The Trustees of Columbia University in the City of New York | MELLER, MICHAEL V | 1655 | Non-Final OA | Jan 11, 2023 |
| 18010266 | USE OF BLUE LIGHT FOR INDUCTION OF ANGIOGENESIS | Angio Gbr | LUKJAN, SEBASTIAN X | 3792 | Non-Final OA | Dec 14, 2022 |
| 18009151 | ALZHEIMER'S DISEASE PREVENTION OR TREATMENT WITH LOW INTENSITY AND HIGH FREQUENCY MAGNETIC STIMULATION | Actipulse Neuroscience Inc. | TRAN, LARA LINH | 3791 | Non-Final OA | Dec 08, 2022 |
| 18072385 | OPHTHALMIC DRUG DELIVERY DEVICE | Contactrx LLC | RASSAVONG, ERIC | 3781 | Non-Final OA | Nov 30, 2022 |
| 17989905 | CELL COMPOSITIONS COMPRISING ANTIGEN-SPECIFIC T CELLS FOR ADOPTIVE THERAPY | Neximmune, Inc. | BELYAVSKYI, MICHAIL A | 1644 | Final Rejection | Nov 18, 2022 |
| 17923294 | FRUIT FLY CONTROL | Macquarie University | RAMACHANDRAN, UMAMAHESWARI | 1627 | Final Rejection | Nov 04, 2022 |
| 17979915 | TERRAIN-SENSITIVE ROUTE PLANNING | Wavesense, Inc. | MERLINO, DAVID P | 3665 | Non-Final OA | Nov 03, 2022 |
| 17978082 | TAILORED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEMS FOR CANCER TUMORS, HEREDITARY AND INFECTIOUS DISEASES | Unknown | EBBINGHAUS, BRIANA NOEL | 1632 | Non-Final OA | Oct 31, 2022 |
| 18047506 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | Hoffmann-La Roche, Inc. | SAMSELL, RILLA MARIE | 1624 | Final Rejection | Oct 18, 2022 |
| 17996228 | LARAZOTIDE DERIVATIVES COMPRISING D-AMINO ACIDS | Interlude Biopharma Co. | MIKNIS, ZACHARY J | 1658 | Non-Final OA | Oct 14, 2022 |
| 17907414 | USE OF CONJUGATES COMPRISING TUMOUR-SELECTIVE LIGANDS AND GROUPS CAPABLE OF RELEASING CARBON MONOXIDE (CO), FOR EXERTING IMMUNOMODULATORY EFFECTS IN CANCER TREATMENT | Faculdade De Medicina Da Universidade De Lisboa | WITHERSPOON, SIKARL A | 1692 | Non-Final OA | Sep 27, 2022 |
| 17939634 | METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT | Aveo Pharmaceuticals, Inc. | FORD, VANESSA L | 1674 | Final Rejection | Sep 07, 2022 |
| 17800950 | BASIC DOMAIN-DELETED DNASE1-LIKE 3 AND USES THEREOF | Neutrolis, Inc. | ZINGARELLI, SANDRA | 1653 | Final Rejection | Aug 19, 2022 |
| 17801067 | PRESSURISED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | Chiesi Farmaceutici S.p.A. | JANG, JAEICK | 3785 | Final Rejection | Aug 19, 2022 |
| 17760354 | PRESSURED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | Chiesi Farmaceutici S.P.A | HAGHIGHATIAN, MINA | 1616 | Non-Final OA | Aug 08, 2022 |
| 17786161 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | Orionis Biosciences, Inc. | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | Non-Final OA | Jun 16, 2022 |
| 17786162 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | Orionis Biosciences, Inc. | RZECZYCKI, PHILLIP MATTHEW | 1625 | Final Rejection | Jun 16, 2022 |
| 17756203 | METHODS AND SYSTEMS FOR MANAGING DISTRIBUTION AND TREATMENT OF A FOOD ALLERGY ORAL IMMUNOTHERAPY DRUG | Société des Produits Nestlé S.A. | COLEMAN, CHARLES P. | 3683 | Non-Final OA | May 19, 2022 |
| 17734703 | MESSENGER RNA THERAPEUTICS AND COMPOSITIONS | Greenlight Biosciences, Inc. | ARIETI, RUTH SOPHIA | 1635 | Non-Final OA | May 02, 2022 |
| 17763344 | PD-L1 TARGETED CHIMERIC PROTEINS AND USES THEREOF | Orionis Biosciences, Inc. | HOPKINS, SAMANTHA LAKE | 1641 | Final Rejection | Mar 24, 2022 |
| 17760861 | SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. | SCHMIDT, IZABELA MARIA | 1621 | Non-Final OA | Mar 16, 2022 |
| 17760886 | SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS | Step Pharma S.A.S. | ENGLISH, CONNOR KENNEDY | 1625 | Non-Final OA | Mar 16, 2022 |
| 17630258 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH | Thermalin Inc. | BRADLEY, CHRISTINA | 1654 | Final Rejection | Jan 26, 2022 |
| 17576046 | TREATMENT OF DISEASE BASED ON IMMUNE CELL SEQUENCING | Tgm Life Sciences LLC | PATTERSON, SARAH COOPER | 1675 | Non-Final OA | Jan 14, 2022 |
| 17598570 | CHIMERIC PROTEINS AND CHIMERIC PROTEIN COMPLEXES DIRECTED TO FMS-LIKE TYROSINE KINASE 3 (FLT3) | Orionis Biosciences BV | YU, MISOOK | 1641 | Final Rejection | Sep 27, 2021 |
| 17470160 | OPHTHALMIC ILLUMINATION DEVICE | Contactrx LLC | FARAH, AHMED M | 3792 | Non-Final OA | Sep 09, 2021 |
| 17412070 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | Glaxosmithkline Intellectual Property Development Limited | SCHMITT, MICHAEL J | 1629 | Final Rejection | Aug 25, 2021 |
| 17415248 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | Orionis Biosciences BV | RAMADAN, OMAR | 1678 | Final Rejection | Jun 17, 2021 |
| 17415216 | FLUORINATED BILE ACIDS | The University Of Southampton | MOORE, SUSANNA | 1624 | Non-Final OA | Jun 17, 2021 |
| 17414288 | FORMULATIONS FOR EGG ORAL IMMUNOTHERAPY, METHODS OF MANUFACTURE, AND TREATMENTS FOR EGG ALLERGY | Société des Produits Nestlé S.A. | KOROTCHKINA, LIOUBOV G | 1653 | Non-Final OA | Jun 15, 2021 |
| 17230270 | METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS | Opus Genetics, Inc. | KLINKEL, KORTNEY L | 1627 | Final Rejection | Apr 14, 2021 |
| 17281290 | EXHALATION DELIVERY SYSTEM FOR AND METHOD OF TREATING SINUS DISEASE | Optinose Inc. | ZAMORY, JUSTIN L | 3783 | Final Rejection | Mar 30, 2021 |
| 17172387 | LARAZOTIDE COMPOSITIONS AND METHODS FOR TREATING CANCER | Institut Gustave Roussy | FISCHER, JOSEPH | 1658 | Non-Final OA | Feb 10, 2021 |
| 17171433 | TARGETING OF HUMAN INTERFERON ANTAGONISTS | Center Hospitaler Regional Universitaire De Montpellier | TAYLOR, LIA ELAN | 1641 | Non-Final OA | Feb 09, 2021 |
| 17171426 | TARGETED HUMAN-INTERFERON FUSION PROTEINS | Universitat Osnabruck | DRISCOLL, MAUREEN VARINA | 1644 | Final Rejection | Feb 09, 2021 |
| 17128599 | BISPECIFIC SIGNALING AGENTS AND USES THEREOF | UNIVERSITEIT GENT | GAO, ASHLEY HARTMAN | 1678 | Final Rejection | Dec 21, 2020 |
| 17042512 | BI-FUNCTIONAL PROTEINS AND CONSTRUCTION THEREOF | Orionis Biosciences BV | DUFFY, BRADLEY | 1643 | Non-Final OA | Sep 28, 2020 |
| 16479827 | MAGNETIC PARTICLE-BASED IMMUNOASSAY AND METHODS OF USING THE SAME | Confer Health, Inc. | RAMADAN, OMAR | 1678 | Final Rejection | Jul 22, 2019 |
| 16461680 | USE OF VIRAL VECTORS IN THE TREATMENT OF RETINOBLASTOMA | Hospital Sant Joan De Deu | HILL, KEVIN KAI | 1638 | Non-Final OA | May 16, 2019 |
| 15678823 | SIRNA STRUCTURE FOR MINIMIZING OFF-TARGET EFFECTS AND RELAXING SATURATION OF RNAI MACHINERY AND THE USE THEREOF | Dong Ki Lee | SHIN, DANA H | 1635 | Final Rejection | Aug 16, 2017 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial